Samsung Pharmaceutical veers into DNA-sequencing service market

Published: 2012-08-17 06:56:00

Updated: 2012-08-17 06:56:00

Samsung Pharmaceutical Co., which has been struggling to stay the course amid deepening business recession, is trying to find a breakthrough by joining DNA-sequencing service market with a local biopharmaceutical firm.

Samsung said Tuesday that it signed an agreement with Medizen Humancare to buy a 26 percent stake of Medizen (1 billion won).

Samsung officials hope that Medizen’s human ge...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.